Tech Company Financing Transactions
Affymax Funding Round
Bessemer Venture Partners, Apax Partners and Merlin BioMed Group participated in a $60 million Series D funding round for Affymax. The round was announced on 7/18/2005.
Transaction Overview
Company Name
Announced On
7/18/2005
Transaction Type
Venture Equity
Amount
$60,000,000
Round
Series D
Investors
Proceeds Purpose
The proceeds will give us the ability to aggressively move forward with our Phase 2 clinical program for Hematide in patients with chronic kidney disease and cancer, as well as develop our pipeline of promising peptide product candidates.
Company Information
Company Status
Out of Business
Industry
Biopharmaceutical
Mailing Address
19200 Stevens Creek Blvd. 240
Cupertino, CA 95014
USA
Cupertino, CA 95014
USA
Phone
Website
Email Address
Overview
Affymax is a biopharmaceutical company committed to developing novel drugs to improve the treatment of serious and often life-threatening conditions.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Financial Officer
Mark Thompson
VP - Finance
Karin Walker
VP - General Counsel
Tracy Dunn
Browse more venture capital transactions:
Prev: 7/18/2005: Zazzle venture capital transaction
Next: 7/19/2005: Zoom Systems venture capital transaction
Share this article
Where The Data Comes From
We report on every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs